

## Publikationen aus dem Labor translationale Forschung, Stand August 2023

1. Bauer, M., Vetter, M., Stückrath, K., Yohannes, M., Desalegn, Z., Yalew, T., Bekuretsion, Y., Kenea, T.W., Joffe, M., van den Berg, E.J., Nikulu, J.I., Bakarou, K., Manraj, S.S., Ogunbiyi, O.J., Ekanem, I.-O., Igbinoba, F., Diomande, M., Adebamowo, C., Dzamalala, C.P., Anele, A.A., Zietsman, A., Galukande, M., Foerster, M., dos-Santos-Silva, I., Liu, B., Santos, P., Jemal, A., Abebe, T., Wickenhauser, C., Seliger, B., McCormack, V., Kantelhardt, E.J., 2023. Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa. *Cancer immunology research* 11, 720–731. <https://doi.org/10.1158/2326-6066.CIR-22-0795>
2. Thomssen, C., Vetter, M., Kantelhardt, E.J., Meisner, C., Schmidt, M., Martin, P.M., Clatot, F., Augustin, D., Hanf, V., Paepke, D., Meinerz, W., Hoffmann, G., Wiest, W., Sweep, F.C.G.J., Schmitt, M., Jänicke, F., Loibl, S., Minckwitz, G. von, Harbeck, N., 2023. Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group. *Cancers* 15. <https://doi.org/10.3390/cancers15051580>
3. Bachmann, H.S., Jung, D., Link, T., Arnold, A., Kantelhardt, E., Thomssen, C., Wimberger, P., Vetter, M., Kuhlmann, J.D., 2022. FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer. *Cancers* 14. <https://doi.org/10.3390/cancers14030468>
4. Desalegn, Z., Yohannes, M., Porsch, M., Stückrath, K., Anberber, E., Santos, P., Bauer, M., Addissie, A., Bekuretsion, Y., Assefa, M., Worku, Y., Taylor, L., Abebe, T., Kantelhardt, E.J., Vetter, M., 2022. Intrinsic subtypes in Ethiopian breast cancer patient. *Breast cancer research and treatment* 196, 495–504. <https://doi.org/10.1007/s10549-022-06769-z>
5. Erber, R., Angeloni, M., Stöhr, R., Lux, M.P., Ulbrich-Gebauer, D., Pelz, E., Bankfalvi, A., Schmid, K.W., Walter, R.F.H., Vetter, M., Thomssen, C., Mayr, D., Klauschen, F., Sinn, P., Sotlar, K., Stering, K., Stenzinger, A., Wunderle, M., Fasching, P.A., Beckmann, M.W., Hoffmann, O., Kimmig, R., Harbeck, N., Wuerstlein, R., Ferrazzi, F., Hartmann, A., 2022. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. *International journal of molecular sciences* 23. <https://doi.org/10.3390/ijms23158716>
6. Reinhardt, K., Stückrath, K., Hartung, C., Kaufhold, S., Uleer, C., Hanf, V., Lantzsch, T., Peschel, S., John, J., Pöhler, M., Bauer, M., Bürrig, F.K., Weigert, E., Buchmann, J., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2022. PIK3CA-mutations in breast cancer. *Breast cancer research and treatment* 196, 483–493. <https://doi.org/10.1007/s10549-022-06637-w>
7. Schüler, K., Bethmann, D., Kaufhold, S., Hartung, C., Stückrath, K., Lantzsch, T., Uleer, C., Hanf, V., Peschel, S., John, J., Pöhler, M., Buchmann, J., Bürrig, K.-F., Weigert, E., Thomssen, C., Kantelhardt, E.J., Vetter, M., 2022. Prognostic Value of Tumour-Infiltrating Lymphocytes in an Unselected Cohort of Breast Cancer Patients. *Diagnostics (Basel, Switzerland)* 12. <https://doi.org/10.3390/diagnostics12102527>
8. Berdiel-Acer, M., Maia, A., Hristova, Z., Borgoni, S., Vetter, M., Burmester, S., Becki, C., Michels, B., Abnaof, K., Binenbaum, I., Bethmann, D., Chatziioannou, A., Hasmann, M., Thomssen, C., Espinet, E., Wiemann, S., 2021. Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. *Oncogene* 40, 2651–2666. <https://doi.org/10.1038/s41388-021-01719-3>

9. Bley, N., Schott, A., Müller, S., Misiak, D., Lederer, M., Fuchs, T., Aßmann, C., Glaß, M., Ihling, C., Sinz, A., Pazaitis, N., Wickenhauser, C., Vetter, M., Ungurs, O., Strauss, H.-G., Thomssen, C., Hüttelmaier, S., 2021. IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer. *RNA biology* 18, 391–403. <https://doi.org/10.1080/15476286.2020.1812894>
10. Hartung, C., Porsch, M., Stückrath, K., Kaufhold, S., Staeger, M.S., Hanf, V., Lantsch, T., Uleer, C., Peschel, S., John, J., Pöhler, M., Weigert, E., Buchmann, J., Bürrig, K.-F., Schüler, K., Bethmann, D., Große, I., Kantelhardt, E.J., Thomssen, C., Vetter, M., 2021. Identifying High-Risk Triple-Negative Breast Cancer Patients by Molecular Subtyping. *Breast care (Basel, Switzerland)* 16, 637–647. <https://doi.org/10.1159/000519255>
11. Mitra, D., Vega-Rubin-de-Celis, S., Royla, N., Bernhardt, S., Wilhelm, H., Tarade, N., Poschet, G., Buettner, M., Binenbaum, I., Borgoni, S., Vetter, M., Kantelhardt, E.J., Thomssen, C., Chatziioannou, A., Hell, R., Kempa, S., Müller-Decker, K., Wiemann, S., 2021. Abrogating GPT2 in triple-negative breast cancer inhibits tumor growth and promotes autophagy. *International journal of cancer* 148, 1993–2009. <https://doi.org/10.1002/ijc.33456>
12. Reibold, C.F., Tariku, W., Eber-Schulz, P., Getachew, S., Addisie, A., Unverzagt, S., Wienke, A., Hauptmann, S., Wickenhauser, C., Vetter, M., Jemal, A., Thomssen, C., Kantelhardt, E.J., 2021. Adherence to Newly Implemented Tamoxifen Therapy for Breast Cancer Patients in Rural Western Ethiopia. *Breast care (Basel, Switzerland)* 16, 484–490. <https://doi.org/10.1159/000512840>
13. Bauer, M., Kantelhardt, E.J., Stiewe, T., Nist, A., Mernberger, M., Politt, K., Hanf, V., Lantsch, T., Uleer, C., Peschel, S., John, J., Buchmann, J., Weigert, E., Bürrig, K.-F., Wickenhauser, C., Thomssen, C., Bartel, F., Vetter, M., 2019. Specific allelic variants of SNPs in the MDM2 and MDMX genes are associated with earlier tumor onset and progression in Caucasian breast cancer patients. *Oncotarget* 10, 1975–1992. <https://doi.org/10.18632/oncotarget.26768>
14. Berchtold, E., Vetter, M., Gündert, M., Csaba, G., Fathke, C., Ulbrich, S.E., Thomssen, C., Zimmer, R., Kantelhardt, E.J., 2019. Comparison of six breast cancer classifiers using qPCR. *Bioinformatics (Oxford, England)* 35, 3412–3420. <https://doi.org/10.1093/bioinformatics/btz103>
15. Kuhlmann, J.D., Bachmann, H.S., Link, T., Wimberger, P., Kröber, E., Thomssen, C., Mallé, B., Bethmann, D., Vetter, M., Kantelhardt, E.J., 2019. Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer. *Scientific reports* 9, 12594. <https://doi.org/10.1038/s41598-019-47601-x>
16. Breunig, C., Erdem, N., Bott, A., Greiwe, J.F., Reinz, E., Bernhardt, S., Giacomelli, C., Wachter, A., Kantelhardt, E.J., Beißbarth, T., Vetter, M., Wiemann, S., 2018. TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer. *Molecular oncology* 12, 1447–1463. <https://doi.org/10.1002/1878-0261.12355>
17. Schmitt, M., Wilhelm, O.G., Noske, A., Schricker, G., Napieralski, R., Vetter, M., Aubele, M., Perkins, J., Lauber, J., Ulm, K., Thomssen, C., Martens, J.W.M., Weichert, W., Kiechle, M., 2018. Clinical Validation of PITX2 DNA Methylation to Predict Outcome in High-Risk Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy. *Breast care (Basel, Switzerland)* 13, 425–433. <https://doi.org/10.1159/000493016>
18. Sengal, A.T., Haj Mukhtar, N.S., Vetter, M., Elhaj, A.M., Bedri, S., Hauptmann, S., Thomssen, C., Mohamedani, A.A., Wickenhauser, C., Kantelhardt, E.J., 2018. Comparison of Receptor-Defined Breast Cancer Subtypes Between German and Sudanese Women: A Facility-Based Cohort Study. *Journal of global oncology* 4, 1–12. <https://doi.org/10.1200/JGO.2017.010082>

19. Bernhardt, S., Bayerlová, M., Vetter, M., Wachter, A., Mitra, D., Hanf, V., Lantsch, T., Uleer, C., Peschel, S., John, J., Buchmann, J., Weigert, E., Bürrig, K.-F., Thomssen, C., Korf, U., Beissbarth, T., Wiemann, S., Kantelhardt, E.J., 2017. Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors. *Breast cancer research : BCR* 19, 112.  
<https://doi.org/10.1186/s13058-017-0905-7>
20. Busch, B., Bley, N., Müller, S., Glaß, M., Misiak, D., Lederer, M., Vetter, M., Strauß, H.-G., Thomssen, C., Hüttelmaier, S., 2016. The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family. *Nucleic acids research* 44, 3845–3864.  
<https://doi.org/10.1093/nar/gkw099>
21. Vogiatzi, F., Brandt, D.T., Schneikert, J., Fuchs, J., Grikscheit, K., Wanzel, M., Pavlakis, E., Charles, J.P., Timofeev, O., Nist, A., Mernberger, M., Kantelhardt, E.J., Siebolts, U., Bartel, F., Jacob, R., Rath, A., Moll, R., Grosse, R., Stiewe, T., 2016. Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. *Proceedings of the National Academy of Sciences of the United States of America* 113, E8433-E8442.  
<https://doi.org/10.1073/pnas.1612711114>
22. Kantelhardt, E.J., Mathewos, A., Aynalem, A., Wondemagegnehu, T., Jemal, A., Vetter, M., Knauf, E., Reeler, A., Bogale, S., Thomssen, C., Stang, A., Gemechu, T., Trocchi, P., Yonas, B., 2014. The prevalence of estrogen receptor-negative breast cancer in Ethiopia. *BMC cancer* 14, 895.  
<https://doi.org/10.1186/1471-2407-14-895>
23. Wichmann, H., Güttler, A., Bache, M., Taubert, H., Vetter, M., Würfl, P., Holzhausen, H.J., Eckert, A.W., Kappler, M., Vordermark, D., 2014. Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients. *Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft* 190, 912–918. <https://doi.org/10.1007/s00066-014-0655-8>
24. Jacobs, V.R., Kates, R.E., Kantelhardt, E., Vetter, M., Wuerstlein, R., Fischer, T., Schmitt, M., Jaenicke, F., Untch, M., Thomssen, C., Harbeck, N., 2013. Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer. *Breast cancer research and treatment* 138, 839–850.  
<https://doi.org/10.1007/s10549-013-2496-z>
25. Kantelhardt, E.J., Vetter, M., Schmidt, M., Veyret, C., Augustin, D., Hanf, V., Meisner, C., Paepke, D., Schmitt, M., Sweep, F., Minckwitz, G. von, Martin, P.-M., Jaenicke, F., Thomssen, C., Harbeck, N., 2011. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel. *BMC cancer* 11, 140. <https://doi.org/10.1186/1471-2407-11-140>
26. Aurich, H., Sgodda, M., Kaltwasser, P., Vetter, M., Weise, A., Liehr, T., Brulport, M., Hengstler, J.G., Dollinger, M.M., Fleig, W.E., Christ, B., 2009. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. *Gut* 58, 570–581.  
<https://doi.org/10.1136/gut.2008.154880>
27. Thomssen, C., Harbeck, N., Dittmer, J., Abraha-Spaeth, S.R., Papendick, N., Paradiso, A., Lisboa, B., Jaenicke, F., Schmitt, M., Vetter, M., 2009. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. *Journal of the National Cancer Institute* 101, 1028–1029. <https://doi.org/10.1093/jnci/djp145>
28. Harbeck, N., Schmitt, M., Vetter, M., Krol, J., Paepke, D., Uhlig, M., Paepke, S., Jänicke, F., Geurts-Moespot, A., Minckwitz, G. von, Sweep, F., Thomssen, C., 2008. Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer. *Breast care (Basel, Switzerland)* 3, 11–15.  
<https://doi.org/10.1159/000151734>

29. Kantelhardt, E.J., Grosse, R., Vetter, M., Heinig, A., Holzhausen, H.-J., Kegel, T., Diestelhorst, A., Mende, T., Strauss, H.-G., Thomssen, C., 2007. Brustzentrum Halle/Saale: Gut gerüstet für die Zukunft. Breast care (Basel, Switzerland) 2, 172–174. <https://doi.org/10.1159/000102987>
30. Schunke, D., Span, P., Ronneburg, H., Dittmer, A., Vetter, M., Holzhausen, H.-J., Kantelhardt, E., Krenkel, S., Müller, V., Sweep, F.C.G.J., Thomssen, C., Dittmer, J., 2007. Cyclooxygenase-2 is a target gene of rho GDP dissociation inhibitor beta in breast cancer cells. Cancer research 67, 10694–10702. <https://doi.org/10.1158/0008-5472.CAN-07-1621>
31. Dittmer, A., Vetter, M., Schunke, D., Span, P.N., Sweep, F., Thomssen, C., Dittmer, J., 2006. Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. The Journal of biological chemistry 281, 14563–14572. <https://doi.org/10.1074/jbc.M510527200>
32. Vetter, M., Blumenthal, S.G., Lindemann, R.K., Manns, J., Wesselborg, S., Thomssen, C., Dittmer, J., 2005. Ets1 is an effector of protein kinase Calpha in cancer cells. Oncogene 24, 650–661. <https://doi.org/10.1038/sj.onc.1208234>

#### **Buchbeitrag:**

1. Kantelhardt EJ, Vetter M, Strauß H-G: Mammakarzinomrezidiv und metastasiertes Mammakarzinom; in Wacker J, Sillem M, Bastert G, Beckmann MW (eds): Therapiehandbuch Gynäkologie und Geburtshilfe, 3. Auflage. Berlin, Heidelberg, Springer, 2020, pp 421–437.

#### **Herausgeberschaft:**

1. Tumorbiologie und Diagnostik des primären Mammakarzinoms, Hsgb. Martina Vetter, Eva Kantelhardt, UNI-MED SIENCE, Bremen, 2015, ISBN 978-3-8374-1492-9